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Micro abstract: 20 
 21 
The role of positive lymph node location in NSCLC patients and effects on survival was 22 
assessed. A total of 88 operated patients with unsuspected N2 disease or station 10 23 
lymph nodes were included in this study. No difference was found in survival between 24 
inferior positive mediastinal N2 node patients compared with multilevel N2 disease 25 
patients. The survival of patients with positive hilar disease was similar to the inferior 26 
mediastinal positive N2 group. 27 
  28 
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Surgically treated unsuspected N2-positive NSCLC: role of extent and location of 29 
lymph node metastasis 30 
  31 
Background: The role of surgery in the treatment of non-small cell lung cancer (NSCLC) 32 
that has spread to ipsilateral mediastinal or hilar lymph nodes is controversial. We 33 
examined whether the location of lymph nodes positive for NSCLC in mediastinum or 34 
hilum influences survival of these patients.  35 
 36 
Patients and methods: We reviewed 881 patients and analysed those with unsuspected 37 
N2 disease or hilar (station 10) lymph nodes. The patients were stratified into the following 38 
groups: group A with positive hilar Naruke 10; group B with superior mediastinal and 39 
aortic nodes (Naruke 1, 2, 3, 4, 5 and 6); group C with inferior mediastinal nodes (Naruke 40 
7, 8 and 9); multilevel group D (two or more positive N2 levels). 41 
 42 
Results: A total of 69 pN2 and 19 pN1 patients were included. Progression-free survival 43 
(PFS) was statistically significant better in group B versus group C (P=.044) and group B 44 
versus group D (P=.0086). The overall-survival (OS) of group A did not differ from that of 45 
group C. A statistically significant better OS was between B and D (P=.051). 46 
 47 
Conclusions: Inferior positive mediastinal N2 node patients seem to have an OS and PFS 48 
as poor as multilevel N2 disease patients. The OS and PFS of patients with positive hilar 49 
disease are similar to those in the inferior mediastinal positive N2 group. Superior positive 50 
mediastinal N2 node patients has better OS and PFS than inferior mediastinal positive N2 51 
group. 52 
 53 
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INTRODUCTION 54 
According to the Finnish Cancer Registry, lung cancer is the leading cause of cancer-55 
related deaths in men (21.6%) and the second most common cause in women 56 
(13.5%).1The optimal treatment and prognosis of lung cancer depends on the stage. The 57 
role of surgery in Stage IIIA patients is controversial, especially in mediastinal N2 disease2. 58 
Despite systemic induction chemotherapy3,4, patients with mediastinal lymph node 59 
involvement have a poor prognosis. The correlation of prognosis to location and extent of 60 
mediastinal lymph node involvement is unclear 5-8. Recently, it has been shown that 61 
single-level N2 disease survival differs from that of multilevel N2 disease9. There are also 62 
reports on patients with lower mediastinal metastasis that indicate a significantly better 63 
prognosis than those with upper mediastinal metastasis10.  64 
To further clarify this matter, we retrospectively analysed our patient series to 65 
understand the correlation between the extent of mediastinal disease involvement and 66 
given location of the involvement to progression-free and overall survival.   67 
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Patients and methods 68 
Patients 69 
Between January 2004 and December 2014, 881 patients underwent anatomic R0 lung 70 
resection with mediastinal lymphadenectomy for primary lung cancer in Helsinki University 71 
Hospital. All patients were preoperatively evaluated by a multidisciplinary lung tumour 72 
board for primary operative management. The study group consisted of patients who were 73 
clinically staged as N0 disease. We excluded patients with clinically suspected N1 or N2 74 
disease on imaging or confirmed before resection. Of these, we excluded 34 patients who 75 
had intraparenchymal positive lymph nodes limited to stations 11 or 12 or both. The type of 76 
surgery performed was lobectomy, sleeve or bilobectomy (Table 1). 77 
Methods 78 
For staging, we utilised the 7th edition of the TNM Classification (American Joint 79 
Committee on Cancer, 2009). We defined unsuspected N2 disease as final pathological 80 
N2 without suspected mediastinal lymph node involvement in preoperative examinations. 81 
Every patient was staged with computed tomography (CT). Fifty-four (61.4%) patients 82 
were staged with positron emission tomography PET-CT and selective mediastinoscopy 83 
was performed on three patients (3.4%) patients. Both mediastinoscopy and PET-CT were 84 
performed on two (2.3%) patients. Preoperative evaluations included a spirometry test 85 
(according to the guidelines of the European Respiratory Society and measurements of 86 
pulmonary diffusing capacity for carbon monoxide (DLCO) using the single-breath method 87 
(American Thoracic Society Guidelines, 1996). Naruke lymph node map was used for 88 
classification11, on which station 10 lymph nodes were regarded as N1 nodes (hilar, main 89 
bronchus nodes). The sites of N2 lymph nodes were grouped as follows: superior 90 
mediastinal (station 1, highest mediastinal nodes; station 2, upper paratracheal nodes; 91 
station 3, pre-vascular and retrotracheal; station 4, lower paratracheal nodes; station 5, 92 
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sub-aortic nodes; and station 6, para-aortic nodes) and inferior mediastinal (station 7, 93 
subcarinal nodes; station 8, paraesophageal nodes; and station 9, pulmonary ligament 94 
nodes) lymph nodes. We excluded nine pneumonectomy patients from our analysis, due 95 
inherent increased morbidity and mortality in the follow-up of this subpopulation. The 96 
patient flowchart is shown in Figure 1 and preoperative data is shown in Table 2. 97 
 98 
LN subclassification 99 
 100 
We classified our patients into the following four groups: group A consisted of pN1 with 101 
positive hilar Naruke 10 (n=19), group B consisted of pN2 patients with superior 102 
mediastinal and aortic positive nodes (Naruke 1, 2, 3, 4, 5 and 6 levels, n=20), group C 103 
consisted of pN2 patients with inferior mediastinal positive nodes (Naruke 7, 8 and 9 104 
levels, n=24) and group D consisted of multilevel pN2 (two or more positive N2 levels, 105 
n=25). 106 
 107 
Statistical analysis 108 
 109 
Statistical analysis was performed using SPSS statistical software (version 22.0, Chicago, 110 
IL, USA). Results are reported as the median (range). Normality was tested using Shapiro-111 
Wilk’s test. The Student’s t-test was used to compare scalar values for groups with normal 112 
distributions. The Mann-Whitney U-test was used for non-normal scalar analysis. 113 
Comparisons of progression free survival (PFS) and overall survival (OS) were performed 114 
using Kaplan-Meier analysis and the log-rank test. A P-value less than .05 was considered 115 
statistically significant. Consent was granted for the study by the hospital scientific review 116 
board.  117 
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Results 118 
A total of 88 patients met the inclusion criteria for this study.  We included 19 hilar pN1 and 119 
69 pN2 patients in our final analysis (Figure 1). Tumour characteristics are presented in 120 
Table 2. The incidence of unsuspected pN2 disease was 7.8% in our study. Fourthy-eight 121 
patients (52.3%) received adjuvant chemotherapy; none received postoperative 122 
radiotherapy (RT). Thirty-day mortality was 2.3% (2 patients). Causes of death were stroke 123 
(1 patient) and ARDS (1 patient). The operative morbidity was 27.3%; the most common 124 
morbidity was pneumonia. Tumours were localised in upper lobes (n=42, 47.7%), middle 125 
lobe (n=6, 6.8%) and lower lobes (n=40, 45.5%). Group B and D had the most upper-lobe 126 
tumour affision (n=12 vs n=14, 60% vs 56%, respectively). Lower-lobe affision was most 127 
common in group C (n=16, 66.7%).  128 
The median PFS was 24 months (range, 0-133 months). The 5-year PFS rates were 129 
21.1% (group A), 30% (group B), 12.5% (group C) and 12% (group D). No statistically 130 
significant difference in PFS was observed between groups A and B (P=.170), A and C 131 
(P=.625), A and D (P=.420) or C and D (P=.735). PFS was statistically significant better in 132 
group B versus group C (P=.044) (Figure 2) and group B versus group D (P=.0086) 133 
(Figure 3); the Kaplan-Meier survival plot overlapped for groups C and group D  . 134 
The median OS and the 5-year overall survival (5-year OS) for the whole group were 34.5 135 
months (range, 0-134 months) and 23.9%, respectively. The median OS values were 39 136 
months (group A), 51 months (group B), 33 months (group C) and 22 months (group D). 137 
The 5-year OS rates were 21% (group A), 35% (group B), 16.7% (group C) and 24% 138 
(group D). A statistically significant better OS was between B and D (P=.051) (Figure 4). 139 
There was no statistically significant difference in OS between groups A and B (P=.143), A 140 
and C (P=.846) and C and D (P=.82); the Kaplan-Meier survival plot overlapped for groups 141 
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C and group D (Figure 5 and Figure 6).  142 
 143 
A multivariate Cox regression analysis was performed between groups A, B, C and D 144 
(Table 3). Age and CCI were covariant affecting to OS, i.e. older patients had better OS 145 
than young patients.  No other covariates reached significance (sex, FEV 1%, thoracotomy 146 
vs. VATS, pre.op. stage) (Table 3).   147 
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DISCUSSION 148 
Accurate assessment of lymph node involvement is crucial for treatment and prognosis of 149 
NSCLC. Variability in identifying lymph node stations can lead to ambiguous staging of 150 
lymph node stations. Previous studies have shown that involvement of station number 10 151 
significantly worsens prognosis compared with other N1 diseases and is similar to that of 152 
N2 disease. 12,13,10. We sought to determine the correlation between the extent of 153 
mediastinal disease involvement and given location of involvement to progression-free and 154 
overall survival.  We use the Naruke map at our institution and consider those lymph 155 
nodes located around the main bronchus as number 10 (N1).11 156 
The International Association for the Study of Lung Cancer map defines the whole 157 
subcarinal LN as level 7, which in the Naruke map corresponds to both levels 7 and 10 LN. 158 
In the American Joint Committee on Cancer (American Joint Committee on Cancer, 2009) 159 
and Mountain’s map, station number 10 (N1 nodes) is located distally to the mediastinal 160 
pleural reflection.  161 
 Our study group consisted of patients with clinical IA to IIB disease. The 162 
unsuspected N2 involvement of 7.8% is in agreement with those of previous studies 163 
showing that about 10% of patients with clinical N0 NSCLC were confirmed as having 164 
pathologic N2 disease after lobectomy. 14 15-17.  165 
 Our results did not show a statistically significant difference in long-term OS 166 
between single-station pN2 and station number 10 metastasis. This result was also 167 
observed between pN1 and pN2 patients with superior mediastinal and positive aortic 168 
nodes. Our findings are consistent with Rea et al., 18 who reported similar 5-year survival 169 
rates in patients with pN1 and those with single-station N2 (31% and 18% respectively). 170 
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Asamura et al. also reported similar results with 5-year survival rates (54% for pN1 and 171 
48% for pN2).22 We believe that this reflects the similarity of pN1 and single-level pN2 172 
disease in superior mediastinal and aortic lymph node metastasis.  173 
 Riquet et al. analysed 1779 lobectomies and observed that pN2 frequency was 174 
similar regardless of the lobes19. In their material, the overall 5-year survival rate was 175 
30.9% in N2 patients. Asamura et al. demonstrated that the most common site of 176 
metastasis in right, upper-lobe tumours was the lower paratracheal station (74%), whereas 177 
metastases to the subcarinal station were only seen in 13% 20. Superior mediastinal and 178 
subcarinal stations were involved in patients with right, lower-lobe tumours. Left upper-lobe 179 
tumours most commonly metastasised to the aortic pulmonary window (59%), followed by 180 
the para-aortic station (32%) and the subcarinal (21%). The subcarinal station was the 181 
most common for metastasis in left, lower-lobe tumours (58%), with infrequent metastases 182 
to the aortic pulmonary window20. Consistent with the results from Asamura et al., the 183 
affected lobe was also most commonly the upper lobe in our study on patients with 184 
superior mediastinal lymph node metastasis17. With inferior mediastinal lymph node 185 
metastasis, tumours were more likely in the lower lobe (60%) than in the upper lobe, which 186 
is consistent with the findings from Asamura et al. In our study, while group D (multilevel) 187 
tumours were more commonly found in the upper than in the lower lobe, the difference 188 
was not statistically significant. 189 
 In our study, we found out better OS among older patients. This might be because 190 
of that patients were older in group B (single level N2 superior) who had better OS than 191 
group C (single level N2 inferior) or multilevel N2 patients.  192 
 In the present study, we observed statistically significantly better progression free  193 
survival in superior N2 patients than in inferior N2 patients. We find out trend for better 194 
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overall survival between inferior N2 versus superior N2 even though it wasn’t statistically 195 
proven. We did not observe any statistically significant difference in PFS or OS between 196 
inferior N2 versus multilevel N2 or comparing pN1 (10) to superior or inferior pN2 single-197 
station lymph node metastasis. Although there are reports that suggest that subcarinal 198 
lymphadenectomy is not always necessary for tumours of the upper lobes 20, we suggest 199 
that for lymph node sampling, station number 7 is relevant for patient outcome irrespective 200 
of the location of the primary tumour. Our main finding was that inferior positive 201 
mediastinal N2 node patients seem to have as unfavourable OS and PFS as multilevel N2 202 
disease patients and significantly worse prognosis than superior mediastinal node 203 
patients. We also noted that patients with positive hilar disease did not have different PFS 204 
than patients with inferior mediastinal positive N2 disease. Both the location of mediastinal 205 
lymph node metastasis and extent of disease are significant factors in the overall 206 
prognosis of NSCLC after surgery. 207 
 208 
 209 
 210 
Limitations of the study 211 
The most significant limitation is the retrospective study design, even with a prospective 212 
patient registry. A prospective study would be challenging due to the time required to 213 
collect study material, even in a multicentre setting. We also do not have accurate 214 
knowledge regarding the quantity of total lymph nodes in all patients, as with VATS 215 
surgery removal of lymph nodes can be performed in a piecemeal nature. Our sample size 216 
was relatively small but comparable to previous studies in unsuspected N2 disease 14-17; 217 
therefore a risk for type II error exists. We are a specialised high-volume centre and 218 
perform careful lymph node sampling on all NSCLC patients. There was no collective re-219 
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evaluation for micrometastasis in lymph nodes, as this evaluation would be easily biased 220 
due to the retrospective nature of the study and the quality of re-evaluation for N0 and N1 221 
(stations 11 and 12) would not yield a significant new patient cohort for our study.  222 
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Conclusion 223 
The current TNM staging in lung cancer only assesses the localisation of the lymph node 224 
stations for the lymph node examination. It seems, however, that the localisation of the 225 
positive lymph node stations alone is not sufficient for a reliable estimation of survival. In 226 
particular, the number of lymph node stations involved not only affects survival, but also 227 
the anatomic location of the single-level lymph node metastasis. We observed statistically 228 
significant poorer survival in the multilevel N2 patients than the single-station N2-patients. 229 
Inferior positive mediastinal N2 node patients seem to have OS and PFS as poor as 230 
multilevel N2 disease patients.  231 
Clinical practise points 232 
Involvement of station number 10 significantly worsens prognosis compared with other N1 233 
diseases and is similar to that of N2 disease. 10,13,18. Unsuspected mediastinal lymph node 234 
metastasis is found in approximately 10% of patient who have surgery for NSCLC. 14-17. 235 
We found out that inferior positive mediastinal N2 node patients seem to have as 236 
unfavourable OS and PFS as multilevel N2 disease patients and significantly worse 237 
prognosis than upper mediastinal node patients. We also noted that patients with positive 238 
hilar disease did not have different PFS than patients with inferior mediastinal positive N2 239 
disease. We suggest that during lobectomy station number 10 and 7 should be dissected. 240 
  241 
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Figure 1. Patient flowchart 248 
 249 
 250 
 251 
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  256 
 257 
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 262 
  263 
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Figure 2. 264 
Kaplan-Meier plot comparing progression free survival for pN2 single level superior (group 265 
B) patients (n=20) to pN2 single level inferior (group C) patients (n=24) (P=.044). 266 
 267 
 268 
 269 
 270 
271 
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Figure 3. 272 
  273 
Kaplan-Meier plot comparing progression free survival for pN2 single level superior (group 274 
B) patients (n=20) to pN2 multilevel (group D) patients (n=25) (P=.0086) 275 
 276 
  277 
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Figure 4. 278 
 279 
Kaplan-Meier plot comparing overall survival for pN2 single level superior (group B) 280 
patients (n=20) to pN2 multilevel (group D) patients (n=25) (P=.051). 281 
  282 
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Figure 5. 283 
Kaplan-Meier plot comparing overall survival between pN2 single level inferior (group C) 284 
patients (n=24) to pN2 multi-level (group D) patients (n=25) (P=.84). 285 
  286 
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Figure 6. 287 
Kaplan-Meier plot comparing overall survival between pN1 hilar (group A) patients (n=19) 288 
vs pN2 single level superior (group B) patients (n=20) vs pN2 single level inferior (group C) 289 
patients (n=24) vs pN2 multi-level (group D) patients (n=25) (P=.26). 290 
  291 
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Table 1. Patient Characteristics  292 
 N (%) 
Mean age (range) 66 (41-83) 
Female 39 (44.3%) 
Type of surgery  
 VATS 23 (26%) 
 Lobectomy 71 (80.7%) 
 Sleeve 11 (12.5%) 
 Bilobectomy 6 (6.8%) 
Site of primary tumour  
 Right lung 58 (65,9%) 
 Right upper lobe 28 (31.8%) 
 Right middle lobe 6 (6.8%) 
 Right lower lobe 24 (27.3%) 
 Left lung 30 (34.1%) 
 Left upper lobe 14 (15.9%) 
 Left lower lobe 16 (18.2%) 
Adjuvant therapy  
 Chemotherapy 46 (52.3%) 
 Radiotherapy 0 (0 %) 
FEV1% (mean) 91% (52-129) 
Charlson Comorbidity Index (CCI) 5.32 (3-10) 
Preop. Stage  
  IA 34 (38.6%) 
 IB 23 (26.1%) 
  IIA 7 (8%) 
 IIB 20 (22.7%) 
  IIIA 4 (4.5%) 
Other co-morbidities  
 Hypertonia 23 (26%) 
 COPD 12 (13.6%) 
 MCC 11 (12.5%) 
 DM 3 (3.4%) 
FEV1=Forced expiratory volume in one second  293 
CCI= Charlson Comorbidity Index  294 
VATS= Video-assisted thoracoscopy surgery  295 
COPD=Chronic obstructive pulmonary disease 296 
MCC= Morbus cordis  297 
DM= Diabetes Mellitus 298 
  299 
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Table 2. Tumour and Operative Characteristics of the 88 Included Patients 300 
 301 
 302 
FEV1=Forced expiratory volume in one second  303 
CCI=Charlson Comorbidity Index 304 
VATS=Video-assisted thoracoscopy surgery  305 
 306 
  307 
 
 
pN1 (group A) 
n=19 
pN2 (group B) 
n=20 
pN2 (group C) 
n=24 
pN2 (group D) 
n=25 
Age (mean) 67 ± 9.2y 66± 9.9y 65 ± 7.1y 68 ± 6y 
Females (%) 6 (31.6%) 10 (50%) 11 (44%) 12 (50%) 
PreOP-FEV1% 85.8% ± 14.3 93.8% ± 15.3 92.6% ± 15.2 91.7% ± 18.9 
Histology 
    
    Squamous Ca 7 (36.8%) 7 (35%) 6 (25%) 6 (24%) 
    Adenoca 11 (57.9%) 13 (65%) 16 (66.7%) 17 (68%) 
    Large Cell Ca 1 (5.3%) 0 (0 %) 2 (8.3%) 2 (8%) 
Localisation, lobe 
    
    Upper 10 12 6 14 
    Medial 2 - 2 2 
    Lower  7 8 16 9 
Type of surgery 
    
 VATS 4 (21%) 6 (30%) 6 (25%) 7 (30%) 
    Lobectomy 14 (73%) 17 (85%) 20 (83.3%) 20 (80%) 
    Bilobectomy 1 (5.3%) 1 (5%) 2 (8.3%) 2 (8%) 
 Sleeve 4 (21.1%) 2 (10%) 2 (8.3%) 3 (12%) 
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Table 3. Multivariate Cox regression analysis of the covariates affecting OS (n=88) 308 
 309 
Table 3. Multivariate Cox regression analysis of the covariates 
affecting OS 
 
 
HR 95%CI P 
Age 1.056 
 
1.013-1.102 
 
 
.011 
 
Sex    1.427 
 
0.716-2.844 
 
 
.313 
 
Preop. FEV1 
 
0.994 
 
0.973-1.015 
 
 
.551 
 
Thoracotomy vs. VATS  0.993 
 
0.706-1.398 
 
 
.970 
 
CCI 1.245 1.046-1.481 .014 
Preop. Stage (vs. Stage IA) 0.887 0.4315-1.823 
 
.7440 
 
 IB 1.281 
 
0.4740-3.463 
 
.6254 
 
 IIA 1.083 
 
0.5105-2.301 
 
.8341 
 
 IIB 0.648 
 
0.1805-2.332 
 
.5073 
 
 IIIA 1.12267 
 
0.5805-2.171 
 
.7310 
 
FEV1=Forced expiratory volume in one second  310 
CCI=Charlson Comorbidity Index 311 
VATS=Video-assisted thoracoscopy surgery  312 
 313 
 314 
 315 
 316 
  317 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
1. Eero, P. & Matti, R. Cancer in Finland. 1–84 (Cancer Society of Finland, 2013). 318 
2. Vansteenkiste, J. et al. Early and locally advanced non-small-cell lung cancer 319 
(NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 320 
Annals of Oncology 24, vi89–vi98 (2013). 321 
3. Albain, K. S. et al. Radiotherapy plus chemotherapy with or without surgical 322 
resection for stage III non-small-cell lung cancer: a phase III randomised controlled 323 
trial. The Lancet 374, 379–386 (2009). 324 
4. MD, P. J. D. B. et al. Standard-dose versus high-dose conformal radiotherapy with 325 
concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for 326 
patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a 327 
randomised, two-by-two factorial phase 3 study. Lancet Oncology 16, 187–199 328 
(2015). 329 
5. Cerfolio, R. J. & Bryant, A. S. Survival of Patients With Unsuspected N2 (Stage IIIA) 330 
Nonsmall-Cell Lung Cancer. Ann. Thorac. Surg. 86, 362–367 (2008). 331 
6. van Klaveren, R. J. et al. Prognosis of unsuspected but completely resectable N2 332 
non-small cell lung cancer. Ann. Thorac. Surg. 56, 300–304 (1993). 333 
7. Ito, M. et al. Classifications of N2 Non–Small-Cell Lung Cancer Based on the 334 
Number and Rate of Metastatic Mediastinal Lymph Nodes. Clinical Lung Cancer 14, 335 
651–657 (2013). 336 
8. Okada, M., Tsubota, N., Yoshimura, M., Miyamoto, Y. & Matsuoka, H. Prognosis of 337 
completely resected pn2 non–small cell lung carcinomas: What is the significant 338 
node that affects survival? The Journal of Thoracic and Cardiovascular Surgery 118, 339 
270–275 (1999). 340 
9. Yoo, C. et al. Prognostic Significance of the Number of Metastatic pN2 Lymph 341 
Nodes in Stage IIIA-N2 Non-Small-Cell Lung Cancer After Curative Resection. 342 
Clinical Lung Cancer 16, e203–12 (2015). 343 
10. Okada, M. et al. Border between N1 and N2 stations in lung carcinoma: lessons 344 
from lymph node metastatic patterns of lower lobe tumors. The Journal of Thoracic 345 
and Cardiovascular Surgery 129, 825–830 (2005). 346 
11. Naruke, T., Suemasu, K. & Ishikawa, S. Lymph node mapping and curability at 347 
various levels of metastasis in resected lung cancer. The Journal of Thoracic and 348 
Cardiovascular Surgery 76, 832–839 (1978). 349 
12. Rea, F. et al. Prognostic significance of main bronchial lymph nodes involvement in 350 
non-small cell lung carcinoma: N1 or N2? Lung Cancer 45, 215–220 (2004). 351 
13. Asamura, H., Suzuki, K., Kondo, H. & Tsuchiya, R. Where is the boundary between 352 
N1 and N2 stations in lung cancer? Ann. Thorac. Surg. 70, 1839–1846 (2000). 353 
14. Fiorelli, A. et al. Incidence, Risk Factors, and Analysis of Survival of Unexpected N2 354 
Disease in Stage I Non–Small Cell Lung Cancer. The Thoracic and Cardiovascular 355 
Surgeon 63, 558–567 (2015). 356 
15. Cerfolio, R. J., Bryant, A. S. & Minnich, D. J. Complete Thoracic Mediastinal 357 
Lymphadenectomy Leads to a Higher Rate of Pathologically Proven N2 Disease in 358 
Patients With Non-Small Cell Lung Cancer. ATS 94, 902–906 (2012). 359 
16. Zhong, C., Yao, F. & Zhao, H. Clinical Outcomes of Thoracoscopic Lobectomy for 360 
Patients With Clinical N0 and Pathologic N2 Non-Small Cell Lung Cancer. ATS 95, 361 
987–992 (2013). 362 
17. Obiols, C. et al. Survival of patients with unsuspected pN2 non-small cell lung 363 
cancer after an accurate preoperative mediastinal staging. Ann. Thorac. Surg. 97, 364 
957–964 (2014). 365 
18. Rea, F. et al. Prognostic significance of main bronchial lymph nodes involvement in 366 
non-small cell lung carcinoma: N1 or N2? Lung Cancer 45, 215–220 (2004). 367 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
19. Riquet, M. et al. Is the lymphatic drainage of lung cancer lobe-specific? A surgical 368 
appraisal. European Journal of Cardio-Thoracic Surgery 47, 543–549 (2015). 369 
20. Asamura, H., Nakayama, H., Kondo, H., Tsuchiya, R. & Naruke, T. Lobe-specific 370 
extent of systematic lymph node dissection for non-small cell lung carcinomas 371 
according to a retrospective study of metastasis and prognosis. The Journal of 372 
Thoracic and Cardiovascular Surgery 117, 1102–1111 (1999). 373 
 374 
 375 
